Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma

Figure 6

Rosuvastatin decreases HIF-1α levels in HCC livers. Representative image of western blot analysis of HIF-1α in normal livers (N), untreated HCC (𝑛=4), and in rosuvastatin-treated HCC livers (𝑛=4) at 16 weeks. The results were normalised to the β-actin levels and expressed as a percentage of HIF-1α levels in normal livers. Data are mean ± SEM. HIF-1α was significantly increased in HCC livers compared with normal livers, ^∗∗∗𝑃<.001. Rosuvastatin decreased significantly HIF-1α levels in HCC livers, ^∗∗𝑃<.01.